According to a new research report “Oral Mucositis (OM) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, OM therapeutics currently exhibits a proliferating pipeline of 23 (excluding marketed drugs) therapeutic candidates.
OM Therapeutics Pipeline Insights
OM is an inflammation of the oral mucosa, which is a common side-effect of chemotherapy and radiotherapy. The inflammation leads to the formation of ulcers and infections in mouth. It usually occurs in the patients with head and neck cancer and lasts for one week to six weeks or more. Lack of nutrition due to inability to eat and severe pain in mouth are some of the problems that occur due to OM.
Other symptoms, such as pain, redness or swelling, blood in mouth, white patches, dry mouth, and diarrhea might be observed with the onset of the disease. Several tests including biopsy and fungal testing are used to diagnose OM. OM can be treated by using pain killer medicines, bland rinses, antiseptic mouth rinses, water-soluble lubricating agents, and mucosal coating agents.
Drug such as Kepivance (Amgen Inc.), a human keratinocyte growth factor, is used for the treatment of OM. Other drugs available for the management of OM includes GelX (Sunstar Suisse SA), NeutraSal (Bausch Health Companies Inc.), Caphosol (Eusa Pharma (UK) Limited), MuGard (Access Pharmaceuticals Inc.), and Episil (Camurus AB).
Insights on Pipeline Segments
According to the research, most of the pipeline drug candidates are being developed for topical administration. It has been found that the topical route is easy to use, non-invasive, and most effective method of administration.
Positive Clinical Trial Results are Expected to Drive the OM Therapeutics Pipeline Advancements
Companies that are involved in developing therapeutics for OM have shown positive clinical results in various phases of drug development. For instance, Galera Therapeutics Inc.’s drug candidate, GC4419, a small molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen, is being developed for the treatment of OM. The results from the phase Ib/IIa clinical trial of GC4419 showed that GC4419 was safe and delayed the onset of severe OM.
Browse Detailed Report at:https://www.pharmaproff.com/report/oral-mucositis-therapeutics-pipeline-analysis
Increasing Approval of Designations is Expected to Accelerate the Growth of OM Therapeutics Pipeline
In February 2018, the U.S. Food and Drug Administration (USFDA) granted Breakthrough Therapy designation to GC4419 to treat patients with OM. The Breakthrough Therapy provides intensive USFDA guidance for efficient drug development, and expedites the development and review process of drugs based on supporting clinical data.
Amgen Inc., Galera Therapeutics Inc., Cellceutix Corporation, Daewoong Pharmaceutical Co. Ltd., and Soligenix Inc. are some of the major companies involved in the development of drug candidates for the treatment of OM.
OM Therapeutics Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of OM. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, market estimation, attribute analysis, epidemiology, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the OM therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to OM.